Form 4: Supernus Pharmaceuticals Executive Padmanabh P. Bhatt Reports Stock Transactions

Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities.

Summary

• On January 27, 2025, Padmanabh P. Bhatt exercised options to acquire 2,573 shares of Supernus Pharmaceuticals common stock at $29.61 per share and sold the same amount at an average price of $39.62.
• On January 28, 2025, Bhatt exercised options to acquire 700 shares of Supernus Pharmaceuticals common stock at $29.61 per share and sold the same amount at an average price of $39.62.
• Following these transactions, Bhatt directly owns 10,149 shares of common stock.
• Bhatt also holds options to purchase 9,477 shares and 1,650 Performance Share Units.
• The options are exercisable with an exercise price of $29.61 and expire on February 19, 2031.
• The Performance Share Units were awarded on February 22, 2024, and a portion vested upon achievement of individual performance objectives established on June 24, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Positives

• The executive's transactions indicate confidence in the company as they continue to hold a significant number of shares and derivative securities.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• Executive stock option exercises and sales are common across the pharmaceutical industry.
• The specific details of option grants, vesting schedules, and performance-based units vary widely based on company size, performance, and compensation philosophy.
• Comparing Bhatt's transactions to those of executives at similar-sized pharmaceutical companies like Acadia Pharmaceuticals or Neurocrine Biosciences would provide a more detailed benchmark.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of shares available in the market.
• The transactions provide transparency to stakeholders regarding executive compensation and stock ownership.

Key Dates